Product & Service News

Stago Launches New Microparticle Calibration Product

Stago Launches New Microparticle Calibration Product

January 2014, Parsippany, NJ, USA – Diagnostica Stago, Inc. introduces Megamix-Plus SSC (cat # 01078) and Megamix-Plus FSC (cat # 01077), for detection of procoagulant microparticles on both side-scatter and forward-scatter flow cytometers. Microparticles are tissue factor-bearing phospholipid vesicles that are a source of procoagulant phospholipids. Microparticle levels have been studied in several pathologies including cancer, diabetes, sickle cell disorder, and parasitic and viral infections.

Read more
Clarity Peer Group Program for Stago Customers

Clarity Peer Group Program for Stago Customers

Clarity for Stago customers is a fully web based peer group program. Today’s fast paced and hectic diagnostic world demands a product that can quickly identify shifts, trends, and allow for immediate corrective action. Clarity provides all of this and more.

Read more
Meet the STA Compact Max “Innovation born from Expertise”.

Meet the STA Compact Max “Innovation born from Expertise”.

AACC 2013 - STA Compact Max Launch – July, 28th 2013 Houston, TX, home of NASA’s Mission Control, was the perfect place for the launch of Stago’s new STA Compact Max analyzer. “Houston ALL SYSTEMS ARE GO”, the launch was a total success.

Read more
Stago Launches Products for Measurement of Rivaroxaban

Stago Launches Products for Measurement of Rivaroxaban

July 12, 2012, Parsippany, NJ, USA – The STA®–Rivaroxaban Calibrator and Controls are highly specific, automation-ready products for determining the rivaroxaban concentration in plasma when used in conjunction with the STA®-Liquid Anti-Xa assay. This method was shown to have favorable performance with respect to its linearity and coefficient of variation (CV) in a recent publication.1

Read more
Stago Offers Three Factor VII Detection Methods

Stago Offers Three Factor VII Detection Methods

June 29, 2012, Parsippany, NJ, USA – Diagnostica Stago, Inc. announces products to suit a variety of clinical research needs for factor VII (FVII). Factor VII is a zymogen that upon activation to its active form, factor VIIa (FVIIa) together with Tissue Factor (TF) comprises the first step in the extrinsic pathway of blood coagulation leading to thrombin formation and subsequent formation of the fibrin clot. Fibrin clot formation is critical for normal hemostasis to occur. All the methods below, which utilize citrated plasma, provide researchers with additional tools to investigate FVII biology, structure and function.

Read more